Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

Autoinhibited structure

Activated structure

1 structures for Q80UQ2

Entry ID Method Resolution Chain Position Source
AF-Q80UQ2-F1 Predicted AlphaFoldDB

16 variants for Q80UQ2

Variant ID(s) Position Change Description Diseaes Association Provenance
rs3388751413 84 D>V No EVA
rs3388770912 87 N>S No EVA
rs3395832834 109 R>H No EVA
rs31714513 127 P>R No EVA
rs3388754854 153 T>I No EVA
rs232779408 157 A>VRQNPHCSTGP* No EVA
rs3388763706 164 M>V No EVA
rs3388741257 165 R>T No EVA
rs3388763700 173 D>N No EVA
rs3388741287 176 G>E No EVA
rs3388758806 186 N>S No EVA
rs1135249158 236 A>T No EVA
rs3388768194 247 R>I No EVA
rs3388770609 249 L>P No EVA
rs3388768144 256 L>Q No EVA
rs3388768208 267 S>G No EVA

No associated diseases with Q80UQ2

2 regional properties for Q80UQ2

Type Name Position InterPro Accession
domain Ras-associating domain 188 - 278 IPR000159
domain SARAH domain 285 - 332 IPR011524

Functions

Description
EC Number
Subcellular Localization
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category No pathway information available

No GO annotations of cellular component

Name Definition
No GO annotations for cellular component

No GO annotations of molecular function

Name Definition
No GO annotations for molecular function

4 GO annotations of biological process

Name Definition
apoptotic process A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died.
positive regulation of apoptotic process Any process that activates or increases the frequency, rate or extent of cell death by apoptotic process.
regulation of apoptotic process Any process that modulates the occurrence or rate of cell death by apoptotic process.
signal transduction The cellular process in which a signal is conveyed to trigger a change in the activity or state of a cell. Signal transduction begins with reception of a signal (e.g. a ligand binding to a receptor or receptor activation by a stimulus such as light), or for signal transduction in the absence of ligand, signal-withdrawal or the activity of a constitutively active receptor. Signal transduction ends with regulation of a downstream cellular process, e.g. regulation of transcription or regulation of a metabolic process. Signal transduction covers signaling from receptors located on the surface of the cell and signaling via molecules located within the cell. For signaling between cells, signal transduction is restricted to events at and within the receiving cell.

7 homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
Q9NS23 RASSF1 Ras association domain-containing protein 1 Homo sapiens (Human) PR
Q8WWW0 RASSF5 Ras association domain-containing protein 5 Homo sapiens (Human) PR
Q6ZTQ3 RASSF6 Ras association domain-containing protein 6 Homo sapiens (Human) PR
Q5EBH1 Rassf5 Ras association domain-containing protein 5 Mus musculus (Mouse) PR
Q99MK9 Rassf1 Ras association domain-containing protein 1 Mus musculus (Mouse) PR
O35141 Rassf5 Ras association domain-containing protein 5 Rattus norvegicus (Rat) PR
Q4QR82 Rassf6 Ras association domain-containing protein 6 Rattus norvegicus (Rat) PR
10 20 30 40 50 60
MTAMDHQFPS WIVVNESTSI SREQLNYLLE TYNVFYENQK NLHILYGQTE DGQLIVEGML
70 80 90 100 110 120
DIFWGVKRPI QLKIQDEKQI SSFDLLNTPE TFSSKGRMTR WGEFDDLYRI SELDRTHVLA
130 140 150 160 170 180
SEARHSPEDY LSYHSTLTPY ADEEPESPLL YRTMSEAALV RKRMRAPEMY RKDRMGVLSN
190 200 210 220 230 240
HRASINGHVY DHETSIFTPT FGSETKVRAN SIMRTEEVIK QLLQKFKIEN SPRDFALYII
250 260 270 280 290 300
FGTGEQRKLK KTDVPLLQRL LQGPSKSNAR IFLMDKDAEE ISRDVAPYIN FHFSFLESIL
310 320 330 340
QRLDEEEKME IERIMAKFNT ERAFILKCLQ SKQAAKTETT V